Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development (Gen3G)
This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3 and 5 year after delivery.
The purpose of this phase 1 is to :
- assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
- assess levels of maternal adipokines as determinants of development and fetal growth;
- determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.
The purpose of this phase 2 is to:
- identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
- identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
- establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
- identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3 and 5 years of age.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|
- Diagnosis of gestational diabetes mellitus [ Time Frame: 24-28 weeks of gestation ] [ Designated as safety issue: No ]75g oral glucose tolerance test
Biospecimen Retention: Samples With DNA
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||January 2019|
|Estimated Primary Completion Date:||January 2019 (Final data collection date for primary outcome measure)|
|Phase 1: Pregnant women|
|Phase 2: Mother-offspring dyad|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01623934
|Centre de recherche Étienne-Le Bel, Centre hospitalier universitaire de Sherbrooke|
|Sherbrooke, Quebec, Canada, J1H5N4|
|Principal Investigator:||Marie-France Hivert, MD, MSc||Université de Sherbrooke|